Intermediate Capital Share Discussion Threads

[mirandaj] 27/5/2024 08:22

Canaccord Genuity reiterated their buy rating on 21st May in a research note  - £30.36

Interesting to see what happens this week.

[zeppo] 23/5/2024 12:30

More from this amazing company!

Grey Wolf Therapeutics closes oversubscribed $50 million Series B financing expansion, led by ICG Life Sciences team, to accelerate and expand first-of-its-kind antigen modulation technology
Brings total Series B funds raised to nearly $100 million
Proceeds to support broadening scope of ongoing clinical trial of GRWD5769; first clinical data to be reported at ASCO 2024
Company to expand R&D efforts to develop disease-modifying therapies for autoimmune disorders
Grey Wolf Therapeutics, a clinical-stage biotechnology company leveraging first-of-its-kind antigen modulation therapies to address the source of immune dysfunction in oncology and autoimmunity, today announced the closing of an oversubscribed $50 million Series B financing expansion, bringing the total amount of Series B funds raised to $99 million. The Series B expansion round was led by ICG’s Life Sciences team and included further investment from existing investors Pfizer Ventures, Andera Partners, Canaan, Earlybird Venture Capital, Oxford Science Enterprises and British Patient Capital.

Proceeds from the round will be leveraged to broaden the scope of the company’s ongoing Phase 1/2 clinical trial of its lead immuno-oncology candidate, GRWD5769, in a range of solid tumour types. The funding also enables the company to expand research and development (R&D) for its versatile antigen modulation approach into treatments for autoimmune disease indications.
 
Tracy Weightman, Associate Director at ICG, said:

"Grey Wolf is an exciting growth stage UK biotechnology company with a novel and differentiated approach that has the potential to transform the lives of millions of patients globally. This investment demonstrates our commitment to building leading biotechnology companies and enabling them to compete on a global stage. We are pleased to support Grey Wolf through the next stage of its growth journey, enabling the company to advance its clinical development strategy and expand into new therapeutic areas."

[zeppo] 22/5/2024 19:57

hxxps://www.icgam.com › 2024 › 05 › 22 › icg-and-teras-launch-templus-the-first-southern-europe-regional-data-centre-platform

ICG and Teras launch Templus, the first Southern Europe regional data ...
Today

Templus utilises a new business model premised on infrastructure's close-to-end customers, digital security, and the highest standards of sustainability and energy efficiency.

ICG, the global alternative asset manager, and Teras Capital (" Teras "), the investment platform led by successful digital

This and Full Year Results on 28th May: Wow!

[scottishfield] 21/5/2024 12:47

JPMorgan raises Intermediate Capital Group price target to 2,798 (2,277) pence 'overweight'

[its the oxman] 20/5/2024 17:53

No idea re ticker I'm afraid. Seems a bit pointless but there we are.Results fairly close now and aum should be up well over 20% since May 2022 results when the shares almost reached 2500p. Performance fees might not be as much but if the outlook is positive and strong prospects or growth targets are reiterated along with a decent increase in the dividend then why not a new high.

[zeppo] 16/5/2024 21:33

Big dividend increase and this level may be sustained.

[growthpotential] 16/5/2024 20:26

Not sure, possibly great results already priced in. However, will let my winners run, as I also tend to hold my losers!

[pvb] 16/5/2024 18:13

Now over £22 going towards the results on 28th May. Can it be sustained?

[pvb] 14/5/2024 19:26

Europe and UK at an Inflection Point
13 May 2024

[growthpotential] 14/5/2024 15:58

Why did they change the ticker? Big deal

[mirandaj] 12/5/2024 16:40

After results



"4-7 June 2024
InterContinental Hotel, Berlin

SuperReturn International is private capital’s most senior gathering, with attendees from 70+ countries and a quality and quantity of LPs and GPs that can’t be found elsewhere."

[its the oxman] 07/5/2024 20:13

End of month, 28th

[growthpotential] 07/5/2024 19:42

When are the results?

[its the oxman] 06/5/2024 19:35

Based on 6 Wall Street analysts offering 12 month price targets for Intermediate Capital in the last 3 months. The average price target is 2,370.00p with a high forecast of 2,600.00p and a low forecast of 2,250.00p. The average price target represents a 10.13% change from the last price of 2,152.00p.Let's go for the high forecast. ?

[pvb] 03/5/2024 16:32

Full year results due on 28 May.

[its the oxman] 03/5/2024 11:09

Nice mini spike to 2166p this morning. 2500p if results please remains possible if markets hold up.

[mirandaj] 28/4/2024 09:02

The FTSE 100 private equity fund manager has bought Law Business Research from Levine Leichtman Capital Partners – a buyout firm in Los Angeles. The deal closed last week and has yet to be formally announced.

[its the oxman] 25/4/2024 14:53

Added 1955p. Not too long till the results at end of May. Hoping they read well.

[pvb] 23/4/2024 18:31

Closed today at just £20 again.

[zeppo] 22/4/2024 18:30

Finals 28th May.

[pvb] 19/4/2024 13:29

Rocky markets, rocky share price! Now we are back under £20.

[prokartace] 19/4/2024 10:43

Lol new thread new collapse

[scottishfield] 17/4/2024 13:14

Yes not too bad. I added a few in decent days.

[its the oxman] 17/4/2024 12:00

No problem. And nice to see we haven't sold off too much on the current market wobble.